B+
Bull case
20%
Probability
Target price
$560.00
+52.4% vs current
Analyst consensus median (~$490.41) sits modestly above the anchor, implying limited near-term upside; the spread to the analyst high (560.0) reflects optionality tied to execution and capital allocation. Market tone is cautiously constructive pending earnings and policy signals.
No evidence quality warning is currently attached to this memo.
Quarterly results and guidance can move the stock; date estimated due to lack of published schedule.
Medicare/Medicaid rule changes could compress or expand margins; treated as a near-term policy tail risk.
Large acquisitions or network deals could re-rate scale benefits; timing assumed longer-term absent announced deals.
No formal recommendation provided.